H.C. Wainwright raised its 12-month price objective on Perspective Therapeutics Inc (NYSE: CATX) to $12.00 from $10.00 while retaining a Buy recommendation, according to a firm note released Friday. At the time of the update, CATX shares were trading at $4.26, reflecting a 57.2% advance over the prior week.
The brokerage's move follows an industry development in which Sanofi S.A. announced it has deprioritized Alphamedix, its SSTR2-targeted radioimmunotherapy. H.C. Wainwright interpreted that shift as removing a potential near-term competitor to Perspective's lead program, 212Pb-VMT-α-NET, which it noted is now the only lead-based radioimmunotherapy targeting SSTR2.
H.C. Wainwright highlighted recent clinical data Perspective presented at ASCO GU 2026. In that dataset, 76% of treated patients remained alive without progression. The firm also emphasized a 39% objective response rate observed in Cohort 2, reported irrespective of SSTR2 expression profile.
For context cited by the firm, Sanofi's Alphamedix had previously shown a 57% centrally confirmed objective response rate among SSTR2+ gastroenteropancreatic neuroendocrine tumor - GEP-NET - patients at ESMO 2025. The note also referenced updated results presented by Sanofi/Oranomed showing a 60% objective response rate, which has been part of the background shaping recent market reactions.
Perspective is currently enrolling and dosing patients in Cohort 3 at higher administered activity levels - 6 mCi x 4 - and H.C. Wainwright expects response rates to rise as the cohort matures. The analyst view links the prospect of deeper responses with the higher-dose cohort progression.
The company has attracted several analyst updates following its third-quarter business update. UBS lowered its price target from $18.00 to $7.00 but maintained a Buy rating, citing concerns that increased competition could weigh on commercial adoption of [212Pb] VMT-α-NET in neuroendocrine tumors. Oppenheimer trimmed its target from $14.00 to $13.00 while keeping an Outperform rating; that firm’s action was taken after competitor data were disclosed and may have influenced perceptions of the competitive environment.
Analyst price targets compiled by InvestingPro span a broad range - from $7 to $20 - indicating varied expectations across the sell-side about the program's commercial prospects and the influence of competitors' clinical results. The recent sequence of clinical disclosures and analyst adjustments underscores an active and evolving competitive landscape for SSTR2-directed therapies in neuroendocrine tumors.
Market snapshot: CATX trading at $4.26; one-week move +57.2%.
Data points referenced: ASCO GU 2026 - 76% progression-free survival proportion and 39% objective response rate in Cohort 2; ESMO 2025 - Alphamedix 57% centrally confirmed ORR in SSTR2+ GEP-NET; Sanofi/Oranomed updated result - 60% ORR.